Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Efficiency of intravenous treatment with levofloxacin in patients with MDR pulmonary tuberculosis in the intensive phase of chemotherapy

Dmytro Butov, Mykhailo Kuzhko, Mykola Gumeniuk, Oleksii Denysov, Tetiana Butova
European Respiratory Journal 2021 58: PA3335; DOI: 10.1183/13993003.congress-2021.PA3335
Dmytro Butov
1Kharkiv National Medical University, Kharkiv, Ukraine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dddimad@gmail.com
Mykhailo Kuzhko
2SO “National institute of Phthisiology and Pulmonology named after F. G. Yanovskyi NAMS of Ukraine”, Kiev, Ukraine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mykola Gumeniuk
2SO “National institute of Phthisiology and Pulmonology named after F. G. Yanovskyi NAMS of Ukraine”, Kiev, Ukraine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oleksii Denysov
3Association for Intensive Treatment of Infectious Diseases «INCURE», Kiev, Ukraine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetiana Butova
4Merefa Central District Hospital, Merefa, Ukraine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Aim: To study the effectiveness of intravenous treatment with levofloxacin in patients with multidrug-resistant pulmonary tuberculosis (MDR TB) in the intensive phase of chemotherapy.

Materials and methods: We observed 62 patients with MDR TB. The patients were divided into two groups: group 1 - 32 patients who received lefofloxacin intravenously for 2 months and group 2 - 30 patients who received this drug orally.

Results: It was found that after 2 months from the start of treatment with intravenous administration of levofloxacin, sputum culture conversion was recorded in 14 (43.7%) patients, and after oral administration - in 6 (20%) patients (p <0.05). Cessation of bacterial excretion by the culture method at the end of the intensive phase of treatment was observed in 19 (59.3%) patients in group 1 and 9 (30%) in group 2 (p <0.05).

Measurements and Main Results: Intravenous administration of levofloxacin in the intensive phase of treatment in patients with MDR TB is more effective than the oral form of this drug. The use of the intravenous form of levofloxacin promotes a more rapid cessation of clinical symptoms, an early cessation of bacterial excretion and an X-ray regression of the tuberculous process in the lungs during the intensive phase of treatment.

  • Adults
  • MDR-TB (multidrug-resistant tuberculosis)

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3335.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Efficiency of intravenous treatment with levofloxacin in patients with MDR pulmonary tuberculosis in the intensive phase of chemotherapy
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Efficiency of intravenous treatment with levofloxacin in patients with MDR pulmonary tuberculosis in the intensive phase of chemotherapy
Dmytro Butov, Mykhailo Kuzhko, Mykola Gumeniuk, Oleksii Denysov, Tetiana Butova
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3335; DOI: 10.1183/13993003.congress-2021.PA3335

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Efficiency of intravenous treatment with levofloxacin in patients with MDR pulmonary tuberculosis in the intensive phase of chemotherapy
Dmytro Butov, Mykhailo Kuzhko, Mykola Gumeniuk, Oleksii Denysov, Tetiana Butova
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3335; DOI: 10.1183/13993003.congress-2021.PA3335
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Biological properties of Mycobacterium tuberculosis (Mtb) resistant to biocides
  • Moxifloxacin, as an alternative in the treatment of patients with the newly diagnosed pulmonary TB with monoresistance to pirazinamid, or its intolerance
Show more Tuberculosis and non-tuberculous mycobacterial diseases

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society